Market Announcement



9 July 2019

Medibio Limited (ASX: MEB) – Suspension from Official Quotation

Description

The securities of Medibio Limited ('MEB') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising.

Issued by

Lisa Banh

Senior Adviser, Listings Compliance (Sydney)

medibio

9 July 2019

Lisa Banh ASX Compliance Pty Limited 22 Bridge Street Sydney NSW 2000

By email only: tradinghaltssydney@asx.com.au

Dear Lisa,

REQUEST FOR VOLUNTARY SUSPENSION

Medibio Limited (ASX: **MEB**) (the **Company**) requests an immediate suspension of the Company's ordinary shares (MEB) quoted on the Australian Securities Exchange (ASX) be granted in accordance with ASX Listing Rule 17.2.

The voluntary suspension is requested pending an announcement by the Company to the market regarding a capital raising ("**purpose**") as referred to in the Company's letter dated 4 July 2019.

In accordance with ASX Listing Rule 17.2, the Company provides the following information in relation to the request:

- 1. The voluntary suspension is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated purpose.
- 2. The Company requests that the voluntary suspension remains in place until the earlier of commencement of normal trading on Wednesday, 10 July 2019, or when the announcement regarding the stated purpose is released to the market.
- 3. The Company expects to make the announcement to the market before the commencement of normal trading on Wednesday, 10 July 2019.
- 4. The Company is not aware of any reason why the voluntary suspension should not be granted or of any further information necessary to inform the market about the voluntary suspension.

Please contact me if you require any further information concerning this matter.

Yours sincerely,

Melanie Leydin Company Secretary Medibio Limited